ClinicalTrials.gg
CompletedNCT04710862Updated Jul 24, 2025Results posted

The Effects of Respiratory Training on Voice

An interventional study of Breathing training without a device and Breathing training with a device in Muscle Tension Dysphonia, sponsored by Syracuse University. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Syracuse University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
27
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Primary muscle tension dysphonia is a voice disorder that involves excessive and poorly coordinated muscle activity affecting multiple subsystems that are involved in speech production, in the absence of structural or neurologic abnormalities of the larynx. Primary muscle tension dysphonia (MTD) is one of the most common forms of voice disorders, accounting for at least 40% of patients seen in voice clinics. Perceptually the voice sounds hoarse and strained, with reduced loudness and pitch range, and people with MTD find speaking very effortful and fatiguing. The physiological abnormalities that characterize MTD are considered multifactorial, and include over-activity of muscles in and around the larynx, laryngeal constriction patterns, and abnormal speech breathing patterns. However, standard treatment approaches for MTD primarily address laryngeal function, including repositioning of laryngeal structures, reducing activity in the intrinsic and extrinsic laryngeal muscles, and altering vibratory patterns. Although voice improvement may follow these treatments, many people with MTD show recurrence of voice problems after only a few months, and some do not improve with treatment. These findings highlight the need for alternative treatments that address the respiratory contributions to MTD, which directly affect the phonatory system. The goal of this project is to compare the effects of two respiratory-based training conditions in people with MTD. A randomized group design will be implemented to determine the respiratory and acoustic effects of each condition. We will determine the effects of each condition immediately after and then 3 and 6 months after training completion to assess short- and long-term training effects. We propose that respiratory training will have a positive effect on related laryngeal behavior and voice. The proposed project has the potential to substantially advance the evidence-based treatment options for MTD, providing a vital step toward reducing the debilitating effects of this disorder.

02

Conditions studied

  • Muscle Tension Dysphonia

Browse trials for

Keywords

  • voice
  • voice disorder
  • treatment
  • respiratory
  • muscle tension dysphonia
  • training
03

In context

Voice Disorders

77 studies on the registry are indexed under Voice Disorders; 17 are open to participants now.

This study's enrollment of 27 is below the median of 41 across 54 interventional studies indexed under Voice Disorders.

Browse Voice Disorders studies →

Lead sponsor

Syracuse University is the lead sponsor of 33 studies on the registry; 7 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Ages 18 or older
  • Self-report of general good health other than voice disorder
  • Self-report of normal pulmonary function
  • Non-smoker status for at least the last 5 years
  • English as their primary language to avoid potential linguistically-based differences in acoustic measures of voice
  • Adequate visual acuity (with or without corrective lenses) to read basic graphs and print, as determined with visual screening
  • No evidence of current organic or neurologic laryngeal pathology, as assessed by nasolaryngoscopy examination and reviewed by a laryngologist
  • No prior surgery to the vocal folds
  • Do not report difficulty with swallowing
  • Not currently receiving voice therapy or other voice treatment that cannot be discontinued
  • Do not report a bilateral, severe to profound hearing loss
  • Willingness to be recorded for data collection that is necessary for this study
  • Have a confirming diagnosis of Muscle Tension Dysphonia from an otolaryngologist and speech-language pathologist
  • Demonstrate quantified auditory-perceptual dysphonia and acoustic dysphonia (Cepstral/Spectral Index of Dysphonia) that exceed normative values for the participant's age and sex
  • Based on the nasolaryngoscopy examination and assessment performed by the otolaryngologist, show one or more patterns of supraglottic activity that are consistent with adducted vocal fold hyperfunction
  • Show no evidence of abnormal, incomplete vocal fold closure patterns as determined on the videostroboscopy assessment (patterns of posterior glottal gaps are normal and expected)
  • Show no evidence of additional neurological voice disorders such as spasmodic dysphonia or vocal fold paralysis
  • Show elevated hyolaryngeal position that exceeds normative expectations as determined through quantitative analysis of ultrasonographic laryngeal images measuring change from rest to phonation
  • Demonstrate voice problems that have persisted for ≥2 months
  • Demonstrate self-reported increase in speaking effort
  • Show evidence of speech breathing abnormalities relative to accepted normative values

Exclusion criteria

Exclusion Criteria:

  • Ages 17 or younger
  • Self-report of major health problems
  • Self-report of pulmonary disease such as asthma, , or emphysema
  • Current smoker status or prior smoker status within the last 5 years
  • English not the primary language
  • Inadequate visual acuity (with corrective lenses if applicable) to read basic graphs and print as determined by failing a visual screening
  • Evidence of current organic or neurologic laryngeal pathology, as assessed by nasolaryngoscopy examination and reviewed by a laryngologist
  • Prior surgery to the vocal folds
  • Currently receiving voice therapy or other voice treatment that cannot be discontinued
  • Self-report of a bilateral, severe to profound hearing loss
  • Not willing to be recorded for data collection that is necessary for this study
  • No confirming diagnosis of Muscle Tension Dysphonia from an otolaryngologist and speech-language pathologist
  • Do not demonstrate quantified auditory-perceptual dysphonia and acoustic dysphonia (Cepstral/Spectral Index of Dysphonia) that exceed normative values for the participant's age and sex
  • Based on the nasolaryngoscopy examination and assessment performed by the otolaryngologist, do not show one or more patterns of supraglottic activity that are consistent with adducted vocal fold hyperfunction
  • Show evidence of abnormal, incomplete vocal fold closure patterns as determined on the videostroboscopy assessment (patterns of posterior glottal gaps are normal and expected)
  • Show evidence of additional neurological voice disorders such as spasmodic dysphonia or vocal fold paralysis
  • Do not show elevated hyolaryngeal position that exceeds normative expectations as determined through quantitative analysis of ultrasonographic laryngeal images measuring change from rest to phonation
  • Demonstrate voice problems that have persisted for less than 2 months
  • Do not demonstrate self-reported increase in speaking effort
  • Do not show evidence of speech breathing abnormalities relative to accepted normative values
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
27 participants (actual)

Study arms

  • Active comparator
    Breathing training with a device (Sham Training as Control)

    Respiratory intervention delivered once a week for 6 weeks, after two initial baseline testing sessions. Participants will perform exhalation exercises through a breathing device. Homework activities will be assigned. Post-training testing sessions will also be conducted.

    Behavioral: Breathing training with a device

  • Active comparator
    Breathing training without a device (Respiratory Lung Volume Training)

    Respiratory intervention delivered once a week for 6 weeks, after two initial baseline testing sessions. Participants will receive training on the use of breathing techniques without a device, but with visual feedback throughout training. Homework activities will be assigned. Post-training testing sessions will also be conducted.

    Behavioral: Breathing training without a device

Interventions

  • BehavioralBreathing training without a device

    Breathing training without a mouth device

  • BehavioralBreathing training with a device

    Breathing training with a mouth device

06

What researchers measure

Primary outcomes

  1. Post Training Lung Volume Initiation

    Average level of lung volume at which speech breaths are initiated, expressed in percent vital capacity relative to resting expiratory level.

    Time frame: Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment

  2. Post Training Lung Volume Termination

    Average level of lung volume at which speech breaths are terminated, expressed in percent vital capacity relative to resting expiratory level.

    Time frame: Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment

  3. Post Training Lung Volume Excursion

    Average level of lung volume at which speech breaths are terminated, expressed in percent vital capacity.

    Time frame: Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment

  4. Post Training Cepstral Peak Prominence

    Average energy in first cepstral peak relative to overall cepstral energy, measured in cepstral decibels. The Cepstral Peak Prominence measure indicates the regularity, or periodicity, of the voice, and is calculated from the recorded acoustic voice signal. A low score such as 2.0 indicates lower regularity in the voice, or greater severity of voice disturbance, whereas a higher score indicates greater regularity in the voice, or less severity of voice disturbance. The values of this measure can theoretically range from zero to any positive integer value.

    Time frame: Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment

  5. Post Training Cepstral/Spectral Index of Dysphonia

    The Cepstral/Spectral Index of Dysphonia is a multivariate measure that indicates the acoustic severity of voice, and is calculated from the recorded acoustic voice signal. The scale generally ranges from 0 to 100, although negative values and values greater than 100 are possible. A score of zero or a low score indicates no acoustic dysphonia (no voice abnormality) or little dysphonia, whereas a high score or score of 100 indicates high severity or maximal severity of acoustic dysphonia.

    Time frame: Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment

Secondary outcomes

  1. Post Training Auditory-Perceptual Overall Severity of Voice Disorder

    Auditory-Perceptual Overall Voice Severity is a measure that indicates the perceptual severity of the voice, and is determined by listeners who rate the overall severity of how the voice sounds on a Visual Analog Scale that ranges from 0 to 100. A score of zero or a low score indicates no or little perceived dysphonia (voice abnormality), whereas a high score or score of 100 indicates high or maximal perceived severity of dysphonia.

    Time frame: Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment

  2. Post Training Voice Handicap Index-10

    The Voice Handicap Index-10 is a questionnaire in which the participant rates the amount of handicap they feel from their voice disorder. Each of 10 questions is rated between a score of 0 (no handicap) to 4 (extreme handicap). Total scores on this questionnaire can range between 0 to 40, with a low score indicating that the participant feels low amounts of handicap or life impact from their voice disorder, whereas a high score indicates that a participant feels high amounts of handicap from their voice disorder.

    Time frame: Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment

07

Results

Posted Jul 24, 2025

Participant flow

Participant flow — Overall Study
MilestoneBreathing Training With a Device (Sham Training as Control)Breathing Training Without a Device
Started1212
Completed1212
Not completed00

Outcome measures

PrimaryPost Training Lung Volume Initiation

Average level of lung volume at which speech breaths are initiated, expressed in percent vital capacity relative to resting expiratory level.

Time frame:
Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment
Reported as:
Mean · % vital capacity relative to rest level
Post Training Lung Volume Initiation
% vital capacity relative to rest levelBreathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)
Post Training Lung Volume Initiation21.07 ± 4.9427.04 ± 7.71
Statistical analysis
  • Breathing Training With a Device (Sham Training as Control) vs Breathing Training Without a Device (Respiratory Lung Volume Training) · Mixed Models Analysis · p = <0.0005
PrimaryPost Training Lung Volume Termination

Average level of lung volume at which speech breaths are terminated, expressed in percent vital capacity relative to resting expiratory level.

Time frame:
Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment
Reported as:
Mean · % vital capacity relative to rest level
Post Training Lung Volume Termination
% vital capacity relative to rest levelBreathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)
Post Training Lung Volume Termination-0.44 ± 5.262.29 ± 5.04
Statistical analysis
  • Breathing Training With a Device (Sham Training as Control) vs Breathing Training Without a Device (Respiratory Lung Volume Training) · Mixed Models Analysis · p = <0.0005
PrimaryPost Training Lung Volume Excursion

Average level of lung volume at which speech breaths are terminated, expressed in percent vital capacity.

Time frame:
Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment
Reported as:
Mean · % vital capacity
Post Training Lung Volume Excursion
% vital capacityBreathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)
Post Training Lung Volume Excursion21.51 ± 4.8124.74 ± 6.48
Statistical analysis
  • Breathing Training With a Device (Sham Training as Control) vs Breathing Training Without a Device (Respiratory Lung Volume Training) · Mixed Models Analysis · p = 0.012
PrimaryPost Training Cepstral Peak Prominence

Average energy in first cepstral peak relative to overall cepstral energy, measured in cepstral decibels. The Cepstral Peak Prominence measure indicates the regularity, or periodicity, of the voice, and is calculated from the recorded acoustic voice signal. A low score such as 2.0 indicates lower regularity in the voice, or greater severity of voice disturbance, whereas a higher score indicates greater regularity in the voice, or less severity of voice disturbance. The values of this measure can theoretically range from zero to any positive integer value.

Time frame:
Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment
Reported as:
Mean · decibels (dB)
Post Training Cepstral Peak Prominence
decibels (dB)Breathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)
Post Training Cepstral Peak Prominence4.86 ± 1.105.31 ± 0.81
Statistical analysis
  • Breathing Training With a Device (Sham Training as Control) vs Breathing Training Without a Device (Respiratory Lung Volume Training) · Mixed Models Analysis · p = 0.001
PrimaryPost Training Cepstral/Spectral Index of Dysphonia

The Cepstral/Spectral Index of Dysphonia is a multivariate measure that indicates the acoustic severity of voice, and is calculated from the recorded acoustic voice signal. The scale generally ranges from 0 to 100, although negative values and values greater than 100 are possible. A score of zero or a low score indicates no acoustic dysphonia (no voice abnormality) or little dysphonia, whereas a high score or score of 100 indicates high severity or maximal severity of acoustic dysphonia.

Time frame:
Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment
Reported as:
Mean · units on a scale
Post Training Cepstral/Spectral Index of Dysphonia
units on a scaleBreathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)
Post Training Cepstral/Spectral Index of Dysphonia29.03 ± 14.0621.96 ± 9.76
Statistical analysis
  • Breathing Training With a Device (Sham Training as Control) vs Breathing Training Without a Device (Respiratory Lung Volume Training) · Mixed Models Analysis · p = 0.004
SecondaryPost Training Auditory-Perceptual Overall Severity of Voice Disorder

Auditory-Perceptual Overall Voice Severity is a measure that indicates the perceptual severity of the voice, and is determined by listeners who rate the overall severity of how the voice sounds on a Visual Analog Scale that ranges from 0 to 100. A score of zero or a low score indicates no or little perceived dysphonia (voice abnormality), whereas a high score or score of 100 indicates high or maximal perceived severity of dysphonia.

Time frame:
Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment
Reported as:
Mean · units on a scale
Post Training Auditory-Perceptual Overall Severity of Voice Disorder
units on a scaleBreathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)
Post Training Auditory-Perceptual Overall Severity of Voice Disorder33.29 ± 24.1818.78 ± 12.28
Statistical analysis
  • Breathing Training With a Device (Sham Training as Control) vs Breathing Training Without a Device (Respiratory Lung Volume Training) · Mixed Models Analysis · p = 0.001
SecondaryPost Training Voice Handicap Index-10

The Voice Handicap Index-10 is a questionnaire in which the participant rates the amount of handicap they feel from their voice disorder. Each of 10 questions is rated between a score of 0 (no handicap) to 4 (extreme handicap). Total scores on this questionnaire can range between 0 to 40, with a low score indicating that the participant feels low amounts of handicap or life impact from their voice disorder, whereas a high score indicates that a participant feels high amounts of handicap from their voice disorder.

Time frame:
Assessed after completion of 6-week training period, approximately 7 weeks after baseline assessment
Reported as:
Mean · units on a scale
Post Training Voice Handicap Index-10
units on a scaleBreathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)
Post Training Voice Handicap Index-1014.38 ± 6.6312.13 ± 6.02
Statistical analysis
  • Breathing Training With a Device (Sham Training as Control) vs Breathing Training Without a Device (Respiratory Lung Volume Training) · Mixed Models Analysis · p = 0.328

Adverse events

Collected over Adverse event data were collected over the period in which each participant completed baseline testing, training, and post-testing, or 8 weeks total.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Breathing Training With a Device (Sham Training as Control)0/12 (0%)0/12 (0%)0/12 (0%)
Breathing Training Without a Device (Respiratory Lung Volume Training)0/12 (0%)0/12 (0%)0/12 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)Breathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)Total
Mean60.0 ± 15.455.4 ± 12.658.3 ± 13.9
Sex: Female, Male
Sex: Female, Male(Participants)Breathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)Total
Female7512
Male5712
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Breathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)Total
Hispanic or Latino011
Not Hispanic or Latino121123
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Breathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)Total
American Indian or Alaska Native000
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American000
White121123
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(participants)Breathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)Total
United States121224
Lung Volume Initiation - Relative to Resting Expiratory Level
Lung Volume Initiation - Relative to Resting Expiratory Level(% vital capacity relative to rest level)Breathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)Total
Mean19.01 ± 6.1115.05 ± 7.0017.03 ± 6.56
Lung Volume Termination - Relative to Resting Expiratory Level
Lung Volume Termination - Relative to Resting Expiratory Level(% vital capacity relative to rest level)Breathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)Total
Mean-1.07 ± 4.40-4.55 ± 5.38-2.81 ± 4.89
Lung Volume Excursion
Lung Volume Excursion(% vital capacity relative to rest level)Breathing Training With a Device (Sham Training as Control)Breathing Training Without a Device (Respiratory Lung Volume Training)Total
Mean20.08 ± 4.9419.60 ± 8.0419.84 ± 6.49

6 further baseline measures are reported on the registry.

08

Study locations

1 site
  • Syracuse University
    Syracuse, New York 13244, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Aug 2024, 39 months.

Results were first posted in Jul 2025, 10 months after primary completion.

Of 30 interventional studies with no phase under Voice Disorders, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 48. This study's 39 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 30, 2020
First posted
Jan 15, 2021
StartActual
May 12, 2021
Primary completionActual
Aug 29, 2024
CompletionActual
Sep 23, 2024
Results first posted
Jul 24, 2025
Last update
Jul 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04710862
Lead sponsor
Syracuse University
Responsible party
Soren Lowell (Professor, Syracuse University) — Principal investigator
First posted
Jan 15, 2021
Start date
May 12, 2021
Primary completion
Aug 29, 2024
Completion
Sep 23, 2024
Results posted
Jul 24, 2025
Last update
Jul 24, 2025

Study contacts

Soren Y Lowell, PhD
principal investigator · Syracuse University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion